216 related articles for article (PubMed ID: 23253715)
1. Progression of solitary and multifocal papillary thyroid carcinoma - a retrospective study of 368 patients.
Zheng XQ; Wang C; Xu M; Yu Y; Yun XW; Jia YS; Wei SF; Ren XB; Gao M
Chin Med J (Engl); 2012 Dec; 125(24):4434-9. PubMed ID: 23253715
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY
Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623
[TBL] [Abstract][Full Text] [Related]
3. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
4. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
5. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
6. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
7. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China.
Zheng X; Xia T; Lin L; Gao S; Lee Y; Yu Y; Wei S; Gao M
World J Surg Oncol; 2012 Jun; 10():104. PubMed ID: 22681706
[TBL] [Abstract][Full Text] [Related]
8. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
9. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
11. Correlation between BRAF
Geng J; Wang H; Liu Y; Tai J; Jin Y; Zhang J; He L; Fu L; Qin H; Song Y; Su J; Zhang A; Wen X; Guo Y; Ni X
Sci China Life Sci; 2017 Jul; 60(7):729-738. PubMed ID: 28646474
[TBL] [Abstract][Full Text] [Related]
12. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF
Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F
J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340
[TBL] [Abstract][Full Text] [Related]
14. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
15. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
[TBL] [Abstract][Full Text] [Related]
16. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients.
Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L
Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214
[TBL] [Abstract][Full Text] [Related]
18. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
19. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
[TBL] [Abstract][Full Text] [Related]
20. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]